ライフサイエンスコーパス: TLD

1 TLD in Escherichia coli is accompanied by blocked replic

2 TLD is the mode of action of common anticancer drugs and

3 TLD measurements also displayed comparable agreement wit

4 TLD PEP was assumed to have at least 90% efficacy in pre

5 d developmental roles in other systems-BMP-1/TLD (tolloid) (astacins), MMPs (matrix metalloproteases)

6 se the possibility that members of the BMP-1/TLD family may be involved in activating latent myostati

7 he propeptide resistant to cleavage by BMP-1/TLD proteinases can cause significant increases in muscl

8 bone morphogenetic protein-1/tolloid (BMP-1/TLD) family of metalloproteinases can cleave the myostat

9 The unexpectedly large number of BMP-1/TLD-like protease genes (23) results primarily from expa

10 on domains of all four known mammalian BMP-1/TLD-like proteases [BMP-1, mammalian Tolloid (mTLD), mam

11 human ataxia-telangiectasia like disorder (A-TLD) were derived.

12 f ROS to background levels largely abolished TLD.

13 Due to hard-fought activism, TLD now costs <$45 per person per year in more than 100

14 At 48 weeks after TLD transition, 94% of participants were in care with a

15 cteria from double-stranded DNA breakage and TLD.

16 e opposing effects of SOG inhibiting DPP and TLD processing SOG to release DPP from the inhibitory co

17 on TLD, and 1 (1%) starting TB treatment and TLD after changing from efavirenz-lamivudine-tenofovir.

18 current rifampin-containing TB treatment and TLD+50 was feasible, well tolerated, and achieved high v

19 7.2% [85.5-99.9]) of 36 who were viraemic at TLD start with lamivudine and tenofovir disoproxil fumar

20 the TLD regimen, 101 (5.3%) were viraemic at TLD start.

21 There are similarities between TLD of bacteria and death of eukaryotic cells.

22 or treating myelinating cultures with a Bmp1/TLD inhibitor results in the formation of numerous ectop

23 nstrate that by inactivating gliomedin, Bmp1/TLD functions as an additional regulatory mechanism to e

24 Eliminating the Bmp1/TLD cleavage site in gliomedin or treating myelinating c

25 I, and report crystal structures of the Bye1 TLD bound to Pol II and three different Pol II-nucleic a

26 ist TLD and suggest strategies for combating TLD resistance during chemotherapies.

27 Community TLD was cost-effective in 90% of setting scenarios and c

28 vailability of TLD (referred to as community TLD) might also result in some use of TLD as pre-exposur

29 The modelled effects of community TLD availability based on an assumed high uptake of TLD

30 in which there was lower uptake of community TLD, community TLD is cost-effective in 92% of setting s

31 The introduction of community TLD, enabling greater PEP access, is a promising approac

32 ario, we considered the effects of community TLD.

33 l positive and negative effects of community TLD.

34 was lower uptake of community TLD, community TLD is cost-effective in 92% of setting scenarios.

35 s averted in 64% of scenarios with community TLD.

36 enerated Kaplan-Meier (KM) curves to compare TLD transition by gender from 1) time countries' introdu

37 l to compare three strategies: (1) continued TLD (baseline); (2) immediate switch to tenofovir-lamivu

38 ed on our model, we estimated that continued TLD results in 14.11 undiscounted life-years and costs $

39 Thymineless death (TLD) is the rapid loss of viability in bacterial, yeast,

40 This phenomenon, called thymineless death (TLD), underlies the action of several antibacterial, ant

41 llular condition known as thymineless death (TLD), which is the basis of action for several common an

42 hesis is not required for thymineless death (TLD).

43 he sensitivity of GK11 to thymineless death (TLD).

44 se to thymine starvation [thymineless death (TLD)].

45 Rationale: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy

46 al of the D'Nerva targeted lung denervation (TLD) system in patients with chronic obstructive pulmona

47 Neither T-lymphocyte depletion (TLD) of the bone marrow nor irradiation appeared to infl

48 Despite TLD being the WHO's preferred regimen since 2019, transi

49 ew participants (2%, n = 9/500) discontinued TLD due to adverse events.

50 ed religation of topoisomerase I-linked DNA (TLD) in the presence of camptothecin.

51 of tenofovir, lamivudine, and dolutegravir (TLD) freely and locally available in communities without

52 oxil fumarate, lamivudine, and dolutegravir (TLD).

53 /lamivudine (or emtricitabine)/dolutegravir (TLD).

54 disoproxil fumarate-lamivudine-dolutegravir (TLD) as the preferred first line regimen for adults and

55 receiving tenofovir-lamivudine-dolutegravir (TLD) can result from poor adherence with or without resi

56 Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy

57 switch to tenofovir-lamivudine-dolutegravir (TLD) with a supplementary 50 mg dolutegravir dose or pla

58 Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy

59 An additional 50-mg dose of dolutegravir (TLD+50) is required with rifampin-containing tuberculosi

60 n molecule that contains a tRNA-like domain (TLD) and an internal open reading frame (ORF).

61 that Bye1 binds with its TFIIS-like domain (TLD) to RNA polymerase (Pol) II, and report crystal stru

62 contains a transfer RNA (tRNA)-like domain (TLD), which enters the ribosome as a tRNA and places an

63 z1-Bulli (MCBulli) of the tri-longin domain (TLD) family.

64 ed by placing a thermoluminescent dosimeter (TLD) strip (six TLD chips) on the abdomen of eight patie

65 performed with thermoluminescent dosimeters (TLD) placed inside a CIRS anthropomorphic phantom.

66 EBT3 film and thermoluminescent dosimeters (TLD).

67 with 50 to 60 thermoluminescent dosimeters (TLDs).

68 antom by using thermoluminescent dosimetric (TLD) and CT pencil chamber measurements.

69 e or emtricitabine/dolutegravir TDF/XTC/DTG (TLD) and tenofovir disoproxil fumarate/lamivudine or emt

70 e source of double-strand ends (DSEs) during TLD, as previously proposed; models are suggested.

71 We examined TLD transition by gender across five PEPFAR-supported HI

72 up to 2 mM) inhibited PARP-1/NAD-facilitated TLD religation in a dose-dependent manner.

73 Many explanations for TLD have been advanced, with recent efforts focused on r

74 cleotide excision repair as explanations for TLD.

75 nded DNA were necessary but insufficient for TLD, whereas reduction of ROS to background levels large

76 avir (DTG) patents expiring by 2029, generic TLD will soon be available globally.

77 We compare the generic TLD availability timeline with development timelines for

78 recombination nor SOS induction causes hyper-TLD in recB cells, and RecQ is not the sole source of do

79 persensitivity to thymine deprivation (hyper-TLD) in mutants that lack the UvrD helicase, which oppos

80 We report that hyper-TLD in uvrD cells is partly RecA dependent and cannot be

81 The hyper-TLD of recB cells requires neither RecA nor RecQ, implyi

82 The hyper-TLD of ruvABC cells requires RecA but not RecQ or RecJ.

83 estigated the possible involvement of ROS in TLD.

84 one study visit after the country introduced TLD were included.

85 vivo, Bye1 is recruited to chromatin via its TLD and occupies the 5'-region of active genes.

86 and fork' structure on the ribosome when its TLD moves to the ribosomal P site and translation resume

87 Like TFIIS, Bye1 binds with its TLD to the Pol II jaw and funnel.

88 Occupying the empty A site with its TLD, the tmRNA enters the ribosome with the help of elon

89 enofovir disoproxil fumarate and lamivudine (TLD) has revolutionized global HIV treatment, with more

90 ransition of women to potentially lifesaving TLD has been slower than men at certain clinical sites e

91 anagement of virologic failure on first-line TLD in the 50 countries with the highest prevalence of H

92 repancies between film profile measurements, TLD-derived point-dose readings, and the corresponding d

93 Free community availability of TLD (referred to as community TLD) might also result in

94 model is presented for a molecular basis of TLD.

95 ved cells and may be the underlying cause of TLD.

96 and the SOS DNA-damage response as causes of TLD.

97 py selection (n=14; 30%); 3) continuation of TLD without GRT (n=3; 7%); and 4) empiric switch to a PI

98 Study visits were conducted on the day of TLD transition and 24 and 48 weeks later.

99 ere are limited data on the effectiveness of TLD+50 in individuals with TB/human immunodeficiency vir

100 to meet the care needs in the modern era of TLD.

101 d from the replication origin: the extent of TLD correlates with the progression of damage.

102 Objective: To evaluate the impact of TLD on COPD exacerbations compared with optimal medical

103 tives: To determine the safety and impact of TLD on respiratory adverse events.Methods: We conducted

104 nder from 1) time countries' introduction of TLD and 2) time of TLD eligibility according to local po

105 e current proposals account for only part of TLD and because reactive oxygen species (ROS) are implic

106 rticipation of ROS in the terminal phases of TLD provides a specific example of how ROS contribute to

107 e characterized the onset and progression of TLD in Escherichia coli and found that DNA damage is the

108 -resistance testing was done at the start of TLD regimen and at viral failure (viral load >=50 copies

109 ountries' introduction of TLD and 2) time of TLD eligibility according to local policies.

110 ilability based on an assumed high uptake of TLD resulted in a mean reduction in incidence of 31% (90

111 munity TLD) might also result in some use of TLD as pre-exposure prophylaxis (PrEP) and as antiretrov

112 k of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.

113 with a repeat VL, 85.0% (CI 83.9, 86.1%) on TLD and 58.2% (CI 56.8, 59.8%) on TLE had resuppressed.

114 anged regimens after one year while 52.4% on TLD had a third VL repeated prior to switch (CI 47.2, 57

115 econd-line switch, 27.9% (CI 24.1, 31.5%) on TLD and 66.6% (CI 64.5, 68.9%) on TLE had changed regime

116 ime on ART 3.3 years (IQR 1.7-6.6), 54.6% on TLD and 45.4% on TLE).

117 re significantly higher among individuals on TLD compared to TLE.

118 vides a major impetus for further studies on TLD.

119 nd persistent virological non-suppression on TLD in South Africa and could be cost-effective, especia

120 th persistent virological non-suppression on TLD.

121 ing TB treatment after a median 3.3 years on TLD, and 1 (1%) starting TB treatment and TLD after chan

122 r for people with dolutegravir resistance or TLD continuation for people without dolutegravir resista

123 )) , Photosens((R)) , TOOKAD((R)) soluble or TLD-1433 is critically reviewed.

124 onal as-yet-unknown function of UvrD promote TLD resistance.

125 esults define pathways by which cells resist TLD and suggest strategies for combating TLD resistance

126 thermoluminescent dosimeter (TLD) strip (six TLD chips) on the abdomen of eight patients examined wit

127 IV: 75 (82%) ART-naive participants starting TLD after a median 15 days on TB treatment, 10 (11%) ART

128 Participants starting TLD and rifampin-containing TB treatment were eligible.

129 nt, 10 (11%) ART-naive participants starting TLD and TB treatment, 5 (5%) starting TB treatment after

130 compared to men (80%, p < 0.001) were taking TLD.

131 Costs included GRT (US$157 per test), TLD ($45 per year), tenofovir-lamivudine plus ritonavir-

132 ent transfection assays, we demonstrate that TLD cleaves SOG and that cleavage is stimulated by DPP.

133 secondary axis induction assay, we show that TLD negates the inhibitory effects of SOG/CHD on DPP/BMP

134 ined 3- to 6.5-month window, patients in the TLD group experienced significantly fewer respiratory ad

135 -month window was significantly lower in the TLD group than in the sham group (hazard ratio, 0.35; 95

136 urned-Wdpcp) complex, the interaction of the TLD core subunits Mon1-Ccz1 and Fuzzy-Inturned with Bull

137 suppression 1 year after introduction of the TLD regimen supports the unconditional transition strate

138 Viral load at the start of the TLD regimen was assessed retrospectively and measured at

139 estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics.

140 Radiation risk was estimated based on the TLD readings and expressed as the dose absorbed by parti

141 The map clarifies that the TLD is located near helix 34 and protein S19 of the 30S

142 as tRNA for normal translation, so that the TLD is oriented toward the ORF.

143 oning from NNRTI-based first-line ART to the TLD regimen in the Medecins Sans Frontieres-supported de

144 Of 1892 participants who transitioned to the TLD regimen, 101 (5.3%) were viraemic at TLD start.

145 surveillance after mass transitioning to the TLD regimen.

146 ibosome and the tmRNA at the point where the TLD is accommodated into the ribosomal P site.

147 At 1 year, the TLD group had less dyspnea (>1-point improvement in Tran

148 The mean PSDs measured with the TLDs were 1.0+/-0.5 Gy in the RAO and 1.5+/-0.4 Gy in th

149 ition those on NNRTI-based first-line ART to TLD without viral load testing.

150 ho were transitioned from NNRTI-based ART to TLD.

151 We conclude that ROS contribute to TLD by converting single-stranded DNA lesions into doubl

152 vir dose adjustment in patients switching to TLD who failed first-line TEE.

153 stance during 1 year following transition to TLD without previous viral load testing.

154 Saharan Africa and eligible to transition to TLD, fewer women (68%) compared to men (80%, p < 0.001)

155 bone morphogenetic protein-1 (BMP1)/Tolloid (TLD)-like proteinases confine Na(+) channel clustering t

156 ic protein 1 (BMP-1) and Drosophila Tolloid (TLD) are prototypes of a family of metalloproteases with

157 ion through 12 months between the treatment (TLD plus optimal medical treatment) and sham control gro

158 e and thymidine, mutant GK11 did not undergo TLD but was defective for in vitro growth, and the defec

159 tify seven critical benchmarks that underpin TLDs' success which novel antiretroviral therapy (ART) s

160 tic processing of fibrillar collagens, while TLD affects dorsal-ventral patterning by releasing TGFbe

161 meet key benchmarks required to compete with TLD.

162 ses for conventional urography measured with TLD strips and calculated as entrance skin dose were 151

163 nt skin doses for CT urography measured with TLD strips and calculated from phantom data (CT dose ind